Metabolites,
Journal Year:
2024,
Volume and Issue:
14(6), P. 325 - 325
Published: June 8, 2024
Epigenetic
and
metabolic
reprogramming
alterations
are
two
important
features
of
tumors,
their
reversible,
spatial,
temporal
regulation
is
a
distinctive
hallmark
carcinogenesis.
Epigenetics,
which
focuses
on
gene
regulatory
mechanisms
beyond
the
DNA
sequence,
new
entry
point
for
tumor
therapy.
Moreover,
drives
hepatocellular
carcinoma
(HCC)
initiation
progression,
highlighting
significance
metabolism
in
this
disease.
Exploring
inter-regulatory
relationship
between
epigenetic
modification
has
become
one
hot
directions
current
research.
As
viral
etiologies
have
given
way
to
dysfunction-associated
steatotic
liver
disease
(MASLD)-induced
HCC,
it
urgent
that
complex
molecular
pathways
linking
them
hepatocarcinogenesis
be
explored.
However,
how
aberrant
crosstalk
modifications
affects
MASLD-induced
HCC
lacks
comprehensive
understanding.
A
better
understanding
linkages
necessary
improve
treatment
strategies.
For
reason,
review
examines
interwoven
landscape
carcinogenesis
context
focusing
regulating
development
interactions
while
also
updating
advances
modification-based
therapeutic
drugs
HCC.
Frontiers in Pharmacology,
Journal Year:
2022,
Volume and Issue:
13
Published: Sept. 2, 2022
Hepatocellular
carcinoma
(HCC)
is
a
highly
mortal
type
of
primary
liver
cancer.
Abnormal
epigenetic
modifications
are
present
in
HCC,
and
RNA
modification
dynamic
reversible
key
post-transcriptional
regulator.
With
the
in-depth
study
modifications,
aberrantly
expressed
human
cancers.
Moreover,
regulators
can
be
used
as
potential
targets
for
cancer
therapy.
In
N6-methyladenosine
(m6A),
N7-methylguanosine
(m7G),
5-methylcytosine
(m5C)
their
have
important
regulatory
roles
HCC
progression
represent
novel
biomarkers
confirmation
diagnosis
treatment
HCC.
This
review
focuses
on
mechanisms
m6A,
m7G,
m5C,
N1-methyladenosine
(m1A),
N3-methylcytosine
(m3C),
pseudouridine
(ψ)
its
development
maintenance.
The
therapeutic
strategies
elaborated
Cancers,
Journal Year:
2022,
Volume and Issue:
14(19), P. 4631 - 4631
Published: Sept. 23, 2022
The
treatment
perspectives
of
advanced
hepatocellular
carcinoma
(HCC)
have
deeply
changed
after
the
introduction
immunotherapy.
results
in
responders
show
improved
survival
compared
with
Sorafenib,
but
only
one-third
patients
achieve
a
significant
benefit
from
treatment.
As
tumor
microenvironment
exerts
central
role
shaping
response
to
immunotherapy,
future
goal
HCC
should
be
identify
proxy
hepatic
tissue
condition
that
is
easy
use
clinical
practice.
Therefore,
search
for
biomarkers
are
accurate
predicting
prognosis
will
hot
topic
therapeutic
management
near
future.
Understanding
mechanisms
resistance
immunotherapy
may
expand
patient
population
it,
and
help
researchers
find
new
combination
regimens
improve
patients’
outcomes.
In
this
review,
we
describe
current
knowledge
on
prognostic
non-invasive
related
immune
checkpoint
inhibitors,
focusing
serological
markers
gut
microbiota.
Metabolites,
Journal Year:
2024,
Volume and Issue:
14(6), P. 325 - 325
Published: June 8, 2024
Epigenetic
and
metabolic
reprogramming
alterations
are
two
important
features
of
tumors,
their
reversible,
spatial,
temporal
regulation
is
a
distinctive
hallmark
carcinogenesis.
Epigenetics,
which
focuses
on
gene
regulatory
mechanisms
beyond
the
DNA
sequence,
new
entry
point
for
tumor
therapy.
Moreover,
drives
hepatocellular
carcinoma
(HCC)
initiation
progression,
highlighting
significance
metabolism
in
this
disease.
Exploring
inter-regulatory
relationship
between
epigenetic
modification
has
become
one
hot
directions
current
research.
As
viral
etiologies
have
given
way
to
dysfunction-associated
steatotic
liver
disease
(MASLD)-induced
HCC,
it
urgent
that
complex
molecular
pathways
linking
them
hepatocarcinogenesis
be
explored.
However,
how
aberrant
crosstalk
modifications
affects
MASLD-induced
HCC
lacks
comprehensive
understanding.
A
better
understanding
linkages
necessary
improve
treatment
strategies.
For
reason,
review
examines
interwoven
landscape
carcinogenesis
context
focusing
regulating
development
interactions
while
also
updating
advances
modification-based
therapeutic
drugs
HCC.
